ERBB2 and breast cancer: The 5-year OS rates of patients with HR+/HER2+ versus HR-/HER2+ breast cancer in our study were 96.7% and 82.7%, respectively, and the 5-year DFS rates of patients in the two groups were 90% and 73.3%, respectively.